Loading...
XJPX
4595
Market cap196mUSD
Jul 10, Last price  
1,666.00JPY
1D
-0.42%
1Q
-9.55%
Jan 2017
190.62%
IPO
168.71%
Name

Mizuho Medy Co Ltd

Chart & Performance

D1W1MN
XJPX:4595 chart
P/E
9.27
P/S
2.82
EPS
179.80
Div Yield, %
5.98%
Shrs. gr., 5y
Rev. gr., 5y
21.78%
Revenues
11.26b
-1.48%
3,248,000,0003,997,355,0004,083,053,0004,962,189,0005,623,976,0006,425,082,0006,426,910,0004,203,303,00012,886,270,00017,581,830,00010,989,735,00011,429,000,00011,260,000,000
Net income
3.43b
-9.22%
139,000,000317,297,000257,601,000395,205,000660,049,000919,205,000874,344,000306,346,0004,816,772,0007,838,094,0003,774,239,0003,773,000,0003,425,000,000
CFO
1.96b
-41.58%
0215,830,00017,712,000187,282,000877,678,000670,668,000745,001,000295,417,0005,596,506,0006,172,506,0003,991,831,0003,348,000,0001,956,000,000
Dividend
Dec 29, 202650 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
IPO date
Dec 17, 2015
Employees
175
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT